BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26890126)

  • 1. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
    Tausch E; Mertens D; Stilgenbauer S
    Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
    Amaya-Chanaga CI; Rassenti LZ
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.
    Langerbeins P; Groß-Ophoff-Müller C; Herling CD
    Oncol Res Treat; 2016; 39(1-2):18-24. PubMed ID: 26891412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia : treatment concepts in transition].
    Eichhorst B; Hallek M
    Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
    Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
    Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
    Rosenquist R; Cortese D; Bhoi S; Mansouri L; Gunnarsson R
    Leuk Lymphoma; 2013 Nov; 54(11):2351-64. PubMed ID: 23480493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.
    Condoluci A; Rossi D
    Expert Rev Hematol; 2019 Feb; 12(2):89-98. PubMed ID: 30686074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
    Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.
    Tees MT; Flinn IW
    Expert Rev Hematol; 2017 Feb; 10(2):137-146. PubMed ID: 27936980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in the Era of Targeted Therapies in CLL.
    Boddu P; Ferrajoli A
    Curr Hematol Malig Rep; 2018 Apr; 13(2):78-90. PubMed ID: 29473123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.
    Zakrzewska E; Pirog M; Purkot J; Giannopoulos K
    Folia Histochem Cytobiol; 2017; 55(3):95-106. PubMed ID: 28994094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
    Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
    Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.
    Hurtado AM; Chen-Liang TH; Przychodzen B; Hamedi C; Muñoz-Ballester J; Dienes B; García-Malo MD; Antón AI; de Arriba F; Teruel-Montoya R; Ortuño FJ; Vicente V; Maciejewski JP; Jerez A
    Blood Cancer J; 2015 Aug; 5(8):e342. PubMed ID: 26314984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
    Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.
    Kienle D; Benner A; Läufle C; Winkler D; Schneider C; Bühler A; Zenz T; Habermann A; Jäger U; Lichter P; Dalla-Favera R; Döhner H; Stilgenbauer S
    Haematologica; 2010 Jan; 95(1):102-9. PubMed ID: 19951976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.